bebtelovimab

Bebtelovimab (LY-CoV1404) is a neutralizing, fully human IgG1 monoclonal antibody targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. This product binds specifically to a highly conserved epitope on the RBD, blocking the interaction between the spike protein and the human angiotensin-converting enzyme 2 (ACE2) receptor. Bebtelovimab exhibits potent and broad neutralizing activity against various SARS-CoV-2 variants, including Omicron (BA.1/BA.2), Delta, and other earlier strains. In clinical settings, it is utilized to reduce the risk of severe disease progression in high-risk ambulatory patients, such as solid organ transplant recipients.